Journal ArticleDOI
Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys.
About:
This article is published in European Journal of Pharmacology.The article was published on 1984-10-30. It has received 336 citations till now. The article focuses on the topics: Pargyline & MPTP.read more
Citations
More filters
Journal ArticleDOI
Oxidative stress and the pathogenesis of Parkinson's disease
Peter Jenner,C. W. Olanow +1 more
TL;DR: Selegiline may act through a mechanism unrelated to MAO-B to increase neurotrophic factor activity and upregulate molecules such as glutathione, SOD, catalase, and BCL-2 protein, which protect against oxidant stress and apoptosis.
Journal ArticleDOI
The scientific and clinical basis for the treatment of Parkinson disease (2009)
TL;DR: This monograph provides an overview of the management of PD patients, with an emphasis on pathophysiology, and the results of recent clinical trials to provide physicians with an understanding of the different treatment options that are available for managing the different stages of the disease and the scientific rationale of theDifferent approaches.
Journal ArticleDOI
An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines.
TL;DR: Physicians who treat PD patients must now assimilate a considerable body of data to optimally manage patients with this complex disorder and to a variety of new treatment strategies for the management of PD.
Journal ArticleDOI
The effect of deprenyl (selegiline) on the natural history of Parkinson's disease
JW Tetrud,J. W. Langston +1 more
TL;DR: Early deprenyl therapy delays the requirement for antiparkinsonian medication, possibly by slowing progression of the disease.
Journal ArticleDOI
The parkinsonian toxin 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP): a technical review of its utility and safety
Serge Przedborski,Vernice Jackson-Lewis,Ali Naini,Michael W. Jakowec,Giselle M. Petzinger,Reginald W. Miller,Muhammad Akram +6 more
TL;DR: The purpose of this review is to inform the researcher of the hazardous nature of MPTP and to provide guidance for its safe handling and use.
References
More filters
Journal ArticleDOI
Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis
TL;DR: It is proposed that this chemical selectively damages cells in the substantia nigra in patients who developed marked parkinsonism after using an illicit drug intravenously.
Journal ArticleDOI
A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
TL;DR: The N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkey provides a model that can be used to examine mechanisms and explore therapies of parkinsonism and the pathological and biochemical changes produced by NMPTP are similar to the well-established changes in patients with parkinsonistan.
Journal ArticleDOI
Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase.
TL;DR: The neurotoxic chemical MPTP is metabolized by rat brain mitochondrial fractions at a rate of 0.91 +/- 0.02 nmoles/mg protein/min, and the major metabolite has been identified as the 1-methyl-4- phenylpyridinium species.
Journal Article
The pathobiology of Parkinson's disease: biochemical aspects of dopamine neuron senescence.
TL;DR: The evidence that oxy-radicals and monoamine oxidase are potentially cytotoxic is reviewed, and a pathobiology of dopamine neuron senescence in Parkinson's disease is proposed.
Journal ArticleDOI
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine destroys dopamine neurons in explants of rat embryo mesencephalon
TL;DR: Results show that MPTP exerts a relatively selective destructive action in dopamine neurons in vitro, similar to the action observed in humans and monkeys in vivo.